Chromosome translocations that result in gene fusion and expression of the fusion gene products are frequently observed in acute myeloid leukemia (AML). The recurrent translocation t(8;16)(p11;p13) is a cytogenetic hallmark for the M4/M5 subtype of AML that occurs in both de novo AML and therapy-related AML. This subtype of AML is associated with monocytoid blast morphology, erythrophagocytosis, and a poor prognosis, with a median survival of only 2 months.
Despite accurate mapping of the translocation breakpoints, attempts to amplify the MOZ-CBP and CBP-MOZ transcripts using reverse transcriptase-polymerase chain reaction (RT-PCR) was successful only in a limited number of cases. [2] [3] [4] Various explanations, such as low expression or high instability, have been proposed for the failure of RT-PCR analysis. Fluorescence in situ hybridization (FISH) is an alternative method for the detection of a specific translocation and for monitoring minimal residual disease. Although a few cosmid clones in the CBP region have been used as FISH probes 3, 5 to demonstrate the disruption of the CBP gene, no FISH probe targeting MOZ-CBP fusion is currently available to diagnostic laboratories.
Taking advantage of the completed human genome project, we searched the National Center for Biotechnology Information (NCBI) database and identified bacteria-derived artificial chromosome (BAC) clones in the MOZ and CBP regions, respectively. BAC clones with an average insert size of 70-100 kb are ideal material to be used as FISH probes. Using the identified BAC clones, we demonstrated the detection of a MOZ-CBP fusion in two AML patients with an 8;16 translocation. Furthermore, we used this probe set to monitor the disease status during the treatment of a patient who has achieved complete cytogenetic remission for 1.5 years. We also identified a MOZ-CBP transcript by RT-PCR and cDNA sequencing in this patient.
Our new FISH probe set was applied on bone marrow specimens from two AML [6] .
We undertook a database search approach to efficiently identify targeted BAC clones. RP11-108L9 is centromeric and adjacent to the MOZ gene, and RP11-462G12 is telomeric and adjacent to the CBP gene. These two clones from the human BAC library were obtained from Children's Hospital Oakland Research Institute (Oakland, CA, USA). DNA isolated from these clones were labeled with fluorochromes following the protocol described in our previous studies 6 and validated as a FISH probe set on normal controls. This probe set was then used to confirm the 8;16 translocation in both patients. This translocation resulted in a MOZ-CBP fusion, with the fusion signal shown on the derivative chromosome 16 (Figure 1 ). Significant advantages of FISH analysis over conventional karyotype analysis include: (1) a specific FISH probe can provide accurate diagnosis, especially when there is limited amount of metaphase cells and when the chromosome morphology is suboptimal, and (2) FISH probes can be used to analyze not only proliferating metaphase cells but also nondividing interphase cells from bone marrow as well as peripheral blood samples. Once the diagnosis of a MOZ-CBP fusion is established, the MOZ-CBP probe set allows for the detection of a fusion signal in interphase cells from peripheral blood to quantify the abnormal cell population. In fact, interphase FISH is the method of choice for assessing effectiveness of therapy and monitoring minimal residual disease. We used this newly developed probe set to quantify the change of abnormal cell population following the treatment of patient 2.
Although only a few studies described successful amplification of the fusion transcripts, these studies led to the identification of two types of MOZ-CBP fusion transcripts. Sequencing analysis revealed that type I transcript represented an in-frame fusion between MOZ exon 16 and CBP exon 3, and type II transcript represented an out-of-frame fusion between MOZ exon 16 and CBP exon 5. 5, 7, 8 Since type I transcript is from an in-frame fusion and is the most successfully detected fusion product, this type of fusion is most likely the critical event in leukemogenesis. Recently, Schmidt et al 5 described a more sensitive RT-PCR assay for the detection of type I MOZ-CBP fusion transcript. Therefore, we used primers MOZ3536F and CBP404R 5 to perform a one-step RT-PCR for the detection of MOZ-CBP fusion transcript from patient 2. We cloned and sequenced the PCR product, and identified a type I transcript (Figure 2 ) with the same MOZ-CBP junction sequence found in two previously reported patients. 7, 8 We demonstrated the effectiveness of using a database-search approach to develop FISH probes for clinical applications. This approach can be extended to any region of interest, because the completed human genome database lists BAC clones covering the entire genome. The newly developed MOZ-CBP probe set is a useful tool for providing accurate diagnosis and for monitoring effectiveness of therapy. The 8;16 translocation has been reported in both de novo AML and therapy-related AML. It is associated with a poor prognosis. Both of our patients had breast cancer before the diagnosis of AML. Patient 1 had complex chromosome abnormalities in addition to an 8;16 translocation. She died shortly after the diagnosis of AML. Patient 2 presented with multiple skin nodules that were composed of leukemic blasts and mild leukopenia about 6 months after receiving radiation and four cycles of cyclophosphamide and doxorubicin for stage II infiltrating duct carcinoma of the breast. A diagnostic bone marrow aspiration and biopsy showed 60% replacement by leukemic blast cells which harbored the t(8;16) translocation. This patient received induction chemotherapy consisting of topotecan, cytarabine, and mitoxantrone given in a timed sequential fashion followed by consolidation therapy with topotecan, cytarabine, and etoposide. Cytogenetic remission was confirmed by G-banding and FISH studies of the marrow. Due to the known poor prognosis for patients with this translocation, this patient proceeded to a matched unrelated donor transplant after conditioning with total body irradiation. She remained in complete cytogenetic remission 1.5 years after induction therapy and 13 months after allogeneic stem cell transplantation. 
MOZ-CBP junction

